SCHEMBL4248353

SCHEMBL4248353

Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3Cl)nn3c2NCC(CO)(CO)C3)ccc1=O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK11 Q15759 13/20 0.54
MAPK13 O15264 9/20 0.54
CYP2C9 P11712 1/20 0.54
MAPK14 Q16539 12/20 0.51
MAPK12 P53778 8/20 0.51
P2RX7 Q99572 2/20 0.35
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR3 P22607 1/20 0.32
TP53 P04637 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
METAP2 P50579 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239907 0.92 MAPK11 (0.56) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4240254 0.88 MAPK11 (0.69) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL29594038 0.88 MAPK11 (0.69) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4237486 0.83 MAPK11 (0.79) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL29593357 0.83 MAPK11 (0.79) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4243482 0.83 MAPK13 (0.53) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL13928910 0.82 MAPK11 (0.53) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL29593890 0.81 MAPK11 (0.65) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4241029 0.81 MAPK11 (0.65) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4243610 0.80 MAPK11 (0.54) MAPK11MAPK13CYP2C9MAPK14MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC (JP) 2009-02-12 US disclosed
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC (JP) 2009-02-12 US disclosed
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC (JP) 2009-02-12 US disclosed
EP-1919919-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN Astellas Pharma Inc. (JP) 2008-05-14 EP disclosed
WO-2007026950-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC. (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN HRH2, OPRD1, HRH4 MAPK11 1195/4885MAPK13 1439/4885CYP2C9 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.